Vakaramoko Diaby to Risk Factors
This is a "connection" page, showing publications Vakaramoko Diaby has written about Risk Factors.
Connection Strength
0.773
-
Sanogo V, Chen Z, Almutairi RD, Hong X, Diaby V. Predictors of 30-day readmission, mortality, and length of stay for hospitalized U.S. patients with Alzheimer's and related dementias from 2010 to 2015. Expert Rev Pharmacoecon Outcomes Res. 2023 Jun; 23(5):555-559.
Score: 0.124
-
Chen Z, Babcock A, Sanogo V, Nelson DR, Xiao H, Diaby V. Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr; 22(3):409-415.
Score: 0.110
-
Babcock A, Moussa RK, Diaby V. Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar; 22(2):247-258.
Score: 0.109
-
Okere AN, Sanogo V, Alqhtani H, Diaby V. Identification of risk factors of 30-day readmission and 180-day in-hospital mortality, and its corresponding relative importance in patients with Ischemic heart disease: a machine learning approach. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct; 21(5):1043-1048.
Score: 0.105
-
Babcock A, Moussa RK, Diaby V. Prevalence and effects of suicidal ideation diagnosis code position in claims on readmission rate estimates. Res Social Adm Pharm. 2021 06; 17(6):1174-1180.
Score: 0.104
-
Nkemdirim Okere A, Sanogo V, Balkrishnan R, Diaby V. A quantitative analysis of the effect of continuity of care on 30-day readmission and in-hospital mortality among patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2020 Sep; 29(9):105053.
Score: 0.102
-
Okere AN, Montesdeoca J, Glasper A, Diaby V. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review. Curr Diabetes Rev. 2018; 14(4):363-375.
Score: 0.086
-
Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. Br J Cancer. 2024 Jun; 130(12):1943-1950.
Score: 0.033